Formula Growth Ltd. Invests $2.79 Million in Lantheus Holdings, Inc. $LNTH

Formula Growth Ltd. bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 25,131 shares of the medical equipment provider’s stock, valued at approximately $2,788,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Jupiter Topco LLC bought a new stake in Lantheus during the 2nd quarter valued at about $575,628,000. Farallon Capital Management LLC grew its stake in Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after acquiring an additional 1,950,252 shares in the last quarter. Norges Bank bought a new position in Lantheus in the 4th quarter worth about $76,197,000. Freestone Grove Partners LP increased its position in shares of Lantheus by 4,114.8% during the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock worth $40,497,000 after acquiring an additional 594,088 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of Lantheus by 440.3% during the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after acquiring an additional 582,661 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Trading Down 0.3%

NASDAQ LNTH opened at $100.47 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The company has a market capitalization of $6.56 billion, a price-to-earnings ratio of 24.27 and a beta of -0.03. The company’s 50-day simple moving average is $103.80 and its two-hundred day simple moving average is $91.51. Lantheus Holdings, Inc. has a one year low of $49.67 and a one year high of $111.86.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. During the same quarter in the previous year, the business posted $1.57 EPS. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. Equities analysts forecast that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. William Blair set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. CJS Securities cut Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. Citizens Jmp restated a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a report on Monday, June 29th. Brookline Capital Markets lowered Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, B. Riley Financial lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, August 17th. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.